Actos, produced by the Japanese pharmaceutical company Takeda Pharmaceuticals, is one of the most popular Type 2 Diabetes medications produced. Unfortunately, Actos has been linked to the increased risk of bladder cancer, and currently the Food and Drug Administration (FDA) is reviewing the safety concerns for users within the United States.
The FDA has announced that patients taking pioglitazone, the active ingredient in Actos, may have an increased risk of developing bladder cancer. Users have filed a lawsuit claiming Takeda Pharmaceutical failed in their duty to adequately warn patients of the increased risk of bladder cancer for those taking Actos.
Under U.S. product liability laws, users, who have developed bladder cancer, may seek legal recourse if they believe they have not been properly warned about the dangers of a product. If users are able to prove their claims against Takeda Pharmaceutical they may be entitled to compensation for their loss.
Pioglitazone is manufactured by Takeda Pharmaceuticals and sold in the United Kingdom and in the United States under the brand name Actos. Other names for the drug are used in other countries. Takeda Pharmaceuticals is the U.S. subsidiary of Takeda Pharmaceutical Company Limited and is currently ranked as one of the top 15 U.S. drug companies with billions of dollars in sales each year.
Although Actos is considered one of the most common drugs prescribed for Type 2 Diabetes, it has been linked to severe health conditions, such as an increased risk of bladder cancer, liver failure, macular edema, bone fractures, and heart failure.
Recent studies suggest patients who take pioglitazone (Actos) for an extended time have an increased risk of bladder cancer. Unfortunately, bladder cancer currently affects approximately 70,000 people each with thousands dying from the condition. According to the Food and Drug Administration, those taking Actos for more than 12 months may have up to a 40% increased risk of getting bladder cancer. Other studies in Great Britain suggest the risk could be much higher. Other countries have recently pulled the medication from their shelves.
Unfortunately, instead of aggressively attempting to solve the increased risks of bladder cancer from Actos, Takeda has taken a wait-and-see attitude. They have, however, recently submitted a new warning label to the FDA that discloses the medication’s risk of causing bladder cancer. The failure of Takeda to fully warn patients of the risks has left thousands of users at risk for this life-threatening medical condition. If you have bladder cancer after taking the medication Actos or experienced other severe side-effects you may have a right to compensation.